Brian Sullivan discussed the FDA approval of REVTORPYK, involving researchers from Fred Hutchinson and the University of Washington.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Brian Sullivan discussed the FDA approval of REVTORPYK, involving researchers from Fred Hutchinson and the University of Washington.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Fred Hutchinson Cancer Center
cancer research institute in Seattle, Washington, United States
Nothing else this week.
-
University of Washington
public research university in Seattle, Washington, United States
Related events
- Experimental therapies require approval from the FDA.
- St. Elizabeth Healthcare provides advanced cancer care in Northern Kentucky, utilizing FDA approval for cutting-edge cancer drugs.
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.